http://purl.org/np/RAj8xCYnG2... RAj8xCYnG2

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#wasAttributedTo wasAttributedTo

https://orcid.org/0000-0002-3668-2627 Elif Ozkan

Elif Ozkan

2022-10-11T07:09:55.889Z

http://purl.org/np/RAj8xCYnG2... RAj8xCYnG2

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#generatedAtTime generatedAtTime

2022-10-11T07:09:55.889987

Elif Ozkan

2022-10-11T07:09:55.889Z

http://purl.org/np/RAj8xCYnG2... RAj8xCYnG2

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#wasQuotedFrom wasQuotedFrom

RETAVASE is indicated for use in acute ST-elevation myocardial infarction (STEMI) to reduce the risk of death and heart failure. It is also indicated for the use of the drug to reduce risk of heart failure and death. The drug is currently being tested in the US for heart failure, stroke, and stroke, among other cardiovascular conditions, in the U.S. and Canada.

Elif Ozkan

2022-10-11T07:09:55.889Z